HTLV-1 Envelope
Description
The E.Coli derived recombinant protein contains the C- terminus of gp46 and most of p21E of HTLV-1. This non-fusion, E. coli-derived protein, starts from HTLV-1 env. Amino acid 165, and is ending in amino acid 440, Mw 27 kDa.
Product Specs
Product Science Overview
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that belongs to the Deltaretrovirus genus. It is primarily known for its association with adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), among other inflammatory conditions . The virus infects a wide range of cells, predominantly CD4+ and CD8+ T-lymphocytes .
The envelope (Env) protein of HTLV-1 plays a crucial role in the virus’s ability to infect host cells. It is composed of two subunits: the surface (SU) glycoprotein and the transmembrane ™ glycoprotein. The SU glycoprotein is responsible for binding to the host cell receptor, while the TM glycoprotein facilitates the fusion of the viral and cellular membranes .
Recombinant HTLV-1 envelope proteins are engineered versions of the natural envelope proteins. These recombinant proteins are produced using various expression systems, such as bacteria, yeast, insect cells, or mammalian cells. The recombinant approach allows for the production of large quantities of the envelope protein, which can be used for research, diagnostic, and therapeutic purposes .
-
Vaccine Development: Recombinant HTLV-1 envelope proteins are being explored as potential vaccine candidates. They can elicit an immune response that targets the virus, providing protection against HTLV-1 infection. Recent studies have shown promising results in animal models, where recombinant envelope proteins have induced neutralizing antibodies and cytotoxic T-cell responses .
-
Diagnostic Tools: Recombinant HTLV-1 envelope proteins are used in diagnostic assays to detect HTLV-1 infection. These proteins can be used as antigens in enzyme-linked immunosorbent assays (ELISAs) to identify antibodies against HTLV-1 in patient samples .
-
Therapeutic Research: The recombinant envelope proteins are also used in therapeutic research to develop treatments for HTLV-1-associated diseases. By understanding how the envelope protein interacts with host cells, researchers can design drugs or antibodies that block these interactions and prevent viral entry .
